Author:
Li Yingying,Wang Shiyuan,Lin Mengmeng,Hou Chunying,Li Chunyu,Li Guohui
Publisher
Springer Science and Business Media LLC
Reference124 articles.
1. Xu BB, He YJ, Wang WL, Zhou CF, Xie SC, Shen DY, Lmcleod H. Research progress of immune checkpoint therapy for cancer. Chin J Clin Pharm Ther (Zhongguo Lin Chuang Yao Li Xue Yu Zhi Liao Xue) 2016; 21(2): 218–234 (in Chinese)
2. Chen P, Lin JG, Dai YB, Zhao AY, Dai YJ, Xu TW. Progress in understanding the relationship between gut microbiota and immune checkpoint inhibitors. Chin J Clin Oncol (Zhongguo Zhong Liu Lin Chuang) 2019; 46(24): 1292–1296 (in Chinese)
3. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018; 50(12): 1–11
4. Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, Jia Y, He Y, Li A, Su C, Ren S, Chen X, Zhou C. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2019; 130: 10–17
5. Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019; 38(1): 255
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献